Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cytek Biosciences Inc (NQ: CTKB )

5.960 +0.040 (+0.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 340,461
Open 5.910
Bid (Size) 5.940 (62)
Ask (Size) 5.960 (91)
Prev. Close 5.920
Today's Range 5.840 - 6.090
52wk Range 3.800 - 9.870
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems
New Enhanced Small Particle (ESP™) Detection Option for Cytek Northern Lights™ and Cytek Aurora™ Systems Expands Capabilities of Small Particle Research 
From Cytek Biosciences, Inc.
Via GlobeNewswire
CTKB Stock Earnings: Cytek Biosciences Misses EPS, Beats Revenue for Q1 2024
CTKB stock results show that Cytek Biosciences missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-32.81%
-32.81%
1 Month
+5.30%
+5.30%
3 Month
-31.65%
-31.65%
6 Month
-14.74%
-14.74%
1 Year
-24.65%
-24.65%

More News

Read More
Cytek Biosciences Reports First Quarter 2024 Financial Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Cytek Biosciences
Via Benzinga
Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
From Cytek Biosciences, Inc.
Via GlobeNewswire
CTKB Stock Earnings: Cytek Biosciences Beats Revenue for Q4 2023
Via InvestorPlace
Cytek® Biosciences Names William McCombe Chief Financial Officer
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
From Cytek Biosciences, Inc.
Via GlobeNewswire
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Participate in Upcoming Investor Conferences
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to present at the 42nd Annual J.P. Morgan Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek's Full Spectrum Technology Stands Out In Cell Analysis Market, Bullish Analyst Says
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
Cytek Biosciences to participate in the Piper Sandler 35th Annual Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Aurora™ CS System Wins BioTech Breakthrough Award for ‘Cell Sorting Product of the Year’
From Cytek Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Cytek Biosciences Reports Third Quarter 2023 Financial Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
Morgan Stanley Maintains Equal-Weight Rating for Cytek Biosciences: Here's What You Need To Know
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.